Drug intelligence / Profile preview

MAb007

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MAb007 is a recombinant monoclonal IgG1 antibody characterized by an unpaired cysteine residue located in its CDR3 variable region. This free cysteine is prone to cysteinylation, a post-translational modification that introduces heterogeneity and adversely affects the antibody's stability and biological activity. Studies have shown that cysteinylation can increase the rate of MAb007 aggregation and decrease the melting temperature of its Fab region. A mild redox step has been identified as an effective method to remove cysteinylation, thereby improving the antibody's homogeneity, stability, and biological activity.

Beyond the preview

Go deeper on MAb007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAb007.

Explore the full profile